Skip to content

Study · Not a test of the peptide alone · 2026

4 results

Hepatic portal venous gas in a patient with diabetes on GLP-1 receptor agonist and alpha-glucosidase inhibitor.

Noguchi T, Okamoto M, Okamoto M, Gotoh K, Masaki T, Shibata H

JCEM case reports5 May 2026

PMID42093866 (opens in a new tab)PMCIDPMC13142154 (opens in a new tab)DOI10.1210/jcemcr/luag070 (opens in a new tab)PepBankPUB-42093866
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 01HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesSafety outcome

    An elderly woman with diabetes developed abdominal pain after acarbose was added to dulaglutide.

    In plain wordsA woman with diabetes developed abdominal pain while receiving dulaglutide plus acarbose.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAbdominal pain
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Following the addition of acarbose, an alpha-glucosidase inhibitor (αGI), the patient developed abdominal pain and nausea.
    2 context sentences
    Summary · context
    An 84-year-old woman, treated with oral hypoglycemic agents for 40 years and insulin therapy for 24 years, presented with frequent constipation due to diabetic autonomic neuropathy.
    Summary · context
    To prevent hypoglycemia, insulin therapy was discontinued, and treatment with dulaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was initiated.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 02HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesSafety outcome

    An elderly woman with diabetes developed nausea after acarbose was added to dulaglutide.

    In plain wordsA woman with diabetes developed nausea while receiving dulaglutide plus acarbose.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableNausea
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Following the addition of acarbose, an alpha-glucosidase inhibitor (αGI), the patient developed abdominal pain and nausea.
    2 context sentences
    Summary · context
    An 84-year-old woman, treated with oral hypoglycemic agents for 40 years and insulin therapy for 24 years, presented with frequent constipation due to diabetic autonomic neuropathy.
    Summary · context
    To prevent hypoglycemia, insulin therapy was discontinued, and treatment with dulaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was initiated.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 03HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesSafety outcome

    An elderly woman with diabetes receiving dulaglutide plus acarbose developed hepatic portal venous gas on CT, without intestinal necrosis or signs of peritoneal irritation.

    In plain wordsA woman with diabetes developed gas in the liver's portal veins while receiving dulaglutide plus acarbose, without intestinal tissue death.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableHepatic portal venous gas
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Abdominal computed tomography revealed HPVG without intestinal necrosis or signs of peritoneal irritation.
    3 context sentences
    Summary · context
    Following the addition of acarbose, an alpha-glucosidase inhibitor (αGI), the patient developed abdominal pain and nausea.
    Summary · context
    An 84-year-old woman, treated with oral hypoglycemic agents for 40 years and insulin therapy for 24 years, presented with frequent constipation due to diabetic autonomic neuropathy.
    Summary · context
    To prevent hypoglycemia, insulin therapy was discontinued, and treatment with dulaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was initiated.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  4. 04HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesOther

    An elderly woman with portal venous gas gradually improved with conservative therapy and withdrawal of dulaglutide and acarbose.

    In plain wordsA woman with portal vein gas gradually improved with supportive treatment after dulaglutide and acarbose stopped.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableClinical improvement after treatment withdrawal
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Conservative therapy, along with the discontinuation of dulaglutide and acarbose, resulted in gradual improvement.
    2 context sentences
    Summary · context
    An 84-year-old woman, treated with oral hypoglycemic agents for 40 years and insulin therapy for 24 years, presented with frequent constipation due to diabetic autonomic neuropathy.
    Summary · context
    To prevent hypoglycemia, insulin therapy was discontinued, and treatment with dulaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was initiated.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.